Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Fried

Showing results (311-320 of 383) with videos related to

Pageof 39
Sort By:
Journal of Hepatology|July 2, 2005
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirinPeter Ferenci, Michael W Fried, Mitchell L Shiffman, et al.
Journal of Hepatology|June 1, 2005
Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year studyRobert G Gish, Huy Trinh, Nancy Leung, et al.
World Journal of Hepatology|October 13, 2018
Chronic hepatitis B virus monoinfection at a university hospital in ZambiaMichael J Vinikoor, Edford Sinkala, Annie Kanunga, et al.
Hepatology (Baltimore, Md.)|June 24, 2008
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirinPaul J Pockros, David Nelson, Eliot Godofsky, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 23, 2023
Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET studyWesam Aleyadeh, Elizabeth C Verna, Hany Elbeshbeshy, et al.
The New England Journal of Medicine|September 27, 2002
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionMichael W Fried, Mitchell L Shiffman, K Rajender Reddy, et al.
Digestive Diseases and Sciences|March 21, 2003
Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis CDickens Theodore, Mitchell L Shiffman, Richard K Sterling, et al.
Antimicrobial Agents and Chemotherapy|August 6, 2014
Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfectionCassandra B Jabara, Fengyu Hu, Katie R Mollan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 29, 2015
HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeNancy Reau, Michael W Fried, David R Nelson, et al.
Hepatology (Baltimore, Md.)|August 13, 2008
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirinMichael W Fried, Donald M Jensen, Maribel Rodriguez-Torres, et al.
Pageof 39

Showing results (311-320 of 383) with videos related to

Sort By:
Pageof 39
Journal of Hepatology|July 2, 2005
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirinPeter Ferenci, Michael W Fried, Mitchell L Shiffman, et al.
Journal of Hepatology|June 1, 2005
Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year studyRobert G Gish, Huy Trinh, Nancy Leung, et al.
World Journal of Hepatology|October 13, 2018
Chronic hepatitis B virus monoinfection at a university hospital in ZambiaMichael J Vinikoor, Edford Sinkala, Annie Kanunga, et al.
Hepatology (Baltimore, Md.)|June 24, 2008
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirinPaul J Pockros, David Nelson, Eliot Godofsky, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 23, 2023
Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET studyWesam Aleyadeh, Elizabeth C Verna, Hany Elbeshbeshy, et al.
The New England Journal of Medicine|September 27, 2002
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionMichael W Fried, Mitchell L Shiffman, K Rajender Reddy, et al.
Digestive Diseases and Sciences|March 21, 2003
Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis CDickens Theodore, Mitchell L Shiffman, Richard K Sterling, et al.
Antimicrobial Agents and Chemotherapy|August 6, 2014
Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfectionCassandra B Jabara, Fengyu Hu, Katie R Mollan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 29, 2015
HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeNancy Reau, Michael W Fried, David R Nelson, et al.
Hepatology (Baltimore, Md.)|August 13, 2008
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirinMichael W Fried, Donald M Jensen, Maribel Rodriguez-Torres, et al.
Pageof 39